SAN DIEGO, Aug. 15, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (“Apricus Bio” or the “Company”) (Nasdaq:APRI) (http://www.apricusbio.com) announced today the receipt of its latest issued Canadian patent, No. 2,512,015, entitled, “Topical Stabilized Prostaglandin E Compound Dosage Forms.” The patent covers a form of the Company’s room temperature technology for its Vitaros® product for the treatment of erectile dysfunction. With receipt of this patent, Apricus Bio has approximately 134 patents granted, and 137 patent applications pending in its worldwide portfolio, covering its NexACT® technology and products.
